Clinical and radiologic correlates of a novel T lymphocyte γ-interferon-activated Ca2+ influx in patients with relapsing-remitting multiple sclerosis

Neurology

Volumn 46, Issue 5, 1996, Pages 1416-1421

  Martino, G ^a   Filippi, M ^a   Martinelli, V ^a   Brambilla, E ^a   Comi, G ^a   Grimaldi, L M E ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CD4 ANTIGEN; GAMMA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELLULAR IMMUNITY; FEMALE; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; T LYMPHOCYTE;

ADOLESCENT; ADULT; BRAIN; CALCIUM; CELL MEMBRANE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; INTERFERON TYPE II; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; RECURRENCE; REFERENCE VALUES; T-LYMPHOCYTES; TIME FACTORS;

EID: 0029895306     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.5.1416     Document Type: Article

References (25)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187.
2. Olsson T. Immunology of multiple sclerosis. Curr Opin Neurol Neurosurg 1992;5:195-202.
3. Cannella B, Raine CS. Cytokines up-regulate la expression in organotypic cultures of central nervous system tissue. J Neuroimmunol 1989;24:239-248.
4. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23: 339-346.
5. Hartung HP, Jung S, Stoll G, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992;40:197-210.
6. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895.
7. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting MS. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
9. Jacobs L, Cookfair D, Rudick R, et al. Results of a phase III trial of IM recombinant beta interferon as treatment for MS [abstract]. J Neuroimmunol 1994;54:170.
10. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
11. 2+ influx in T lymphocytes from patients with multiple sclerosis. Proc Natl Acad Sci USA 1994;91:4825-4829.
12. Tsien RW, Tsien RY. Calcium channels, stores, and oscillations. Annu Rev Cell Biol 1990;6:715-760.
13. 2+-dependent mechanism. J Neuroimmunol 1995;62:169-176.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
15. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 1983; 33:1444-1452.
16. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
17. 2+ influx: two independently regulated mechanisms of influx stimulation coexist in neurosecretory PC12 cells. J Biol Chem 1992;267:2164-2172.
18. Hess SD, Oortgiesen M, Cahalan MD. Calcium oscillation in human T and natural killer cells depend upon membrane potential and calcium influx. J Immunol 1993;130:2620-2633.
19. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669.
20. Smith M, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
21. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
22. Rotnes JS, Aas V, Iversen JG. Interferon-gamma modulates cytosolic free calcium in human neutrophilic granulocytes. Eur J Haematol 1994;53:65-73.
23. Haustein J, Laniado M, Niendorf HP, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 1993;186:855-860.
24. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46: 379-384.
25. McVicar DW, Merchant RE, Merchant LH, Young HF. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro. Cancer Immunol Immunother 1989;29:211-218.